Integer (NYSE:ITGR – Get Free Report) had its price target boosted by investment analysts at Bank of America from $135.00 to $145.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Bank of America‘s target price points to a potential upside of 13.97% from the company’s current price.
Several other research analysts also recently weighed in on ITGR. Truist Financial boosted their price target on Integer from $137.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. Oppenheimer started coverage on Integer in a research note on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 target price for the company. Finally, Benchmark reissued a “buy” rating and issued a $130.00 price target on shares of Integer in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Integer currently has an average rating of “Moderate Buy” and an average price target of $137.29.
Get Our Latest Analysis on ITGR
Integer Stock Up 0.0 %
Integer (NYSE:ITGR – Get Free Report) last issued its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. The business had revenue of $436.20 million during the quarter, compared to the consensus estimate of $437.00 million. Integer had a net margin of 6.31% and a return on equity of 11.48%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 earnings per share. As a group, equities research analysts anticipate that Integer will post 5.31 EPS for the current fiscal year.
Insider Buying and Selling at Integer
In other news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total value of $1,431,133.60. Following the transaction, the director now directly owns 2,280 shares in the company, valued at approximately $272,824.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.00% of the stock is owned by company insiders.
Hedge Funds Weigh In On Integer
Hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new stake in shares of Integer during the 1st quarter valued at about $786,000. Public Employees Retirement Association of Colorado lifted its position in shares of Integer by 3,260.1% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 285,439 shares of the medical equipment provider’s stock worth $28,281,000 after purchasing an additional 276,944 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Integer by 460.4% in the second quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider’s stock valued at $658,000 after purchasing an additional 4,636 shares during the period. UniSuper Management Pty Ltd acquired a new stake in Integer during the 1st quarter valued at $976,000. Finally, Congress Asset Management Co. MA increased its stake in Integer by 12.5% during the 4th quarter. Congress Asset Management Co. MA now owns 421,524 shares of the medical equipment provider’s stock worth $41,765,000 after buying an additional 46,776 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Featured Stories
- Five stocks we like better than Integer
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- What is a SEC Filing?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.